Cocrystal Pharma, Inc. — Director's Dealing 2014

Mar 17, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOZONE PHARMACEUTICALS, INC. (BZNE)
CIK: 0001412486
Period of Report: 2014-03-17

Reporting Person: WILCOX GARY (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (16835237)		Direct

Footnotes

F1: Represents approximately 82,090 shares of Series B preferred stock. The Series B shares automatically convert into 205.08308640 shares of Common Stock when the issuer increases its authorized capital to enable all of the outstanding Series B holders to convert. The Series B shares were issued on January 2, 2014 and do not expire.